Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADME and Bioavailability of LOXO-783 in Healthy Adults
NCT06102512Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Oct 2023
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of LOXO-783 in breast cancer and solid tumor (2 arms), sponsored by Eli Lilly and Company. Primary endpoints: Fraction of Dose Excreted in Urine, Cumulative Fraction of Dose Excreted in Urine and 4 more. Started Oct 2023; status: completed.
02
Drugs
LOXO-783
03
Conditions
breast cancersolid tumor
Beyond the preview
Go deeper on NCT06102512.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06102512.